SCHEMBL3669814

SCHEMBL3669814

NCc1cccc(-c2cncc(Br)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.48
CYP2A6 P11509 3/20 0.45
LOXL2 Q9Y4K0 1/20 0.43
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
GABRG2 P18507 2/20 0.40
GABRB3 P28472 2/20 0.40
GABRA5 P31644 2/20 0.40
GABRA3 P34903 2/20 0.40
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
EPHX2 P34913 1/20 0.40
PRMT6 Q96LA8 1/20 0.40
PNMT P11086 1/20 0.39
ENPP2 Q13822 1/20 0.39
TAAR1 Q96RJ0 2/20 0.39
CFD P00746 2/20 0.38
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666921 0.84 CYP2A6 (0.53) CYP2A6LOXL2CYP11B1CYP11B2TAAR1
SCHEMBL3670438 0.83 PRKCI (0.57) CDK8CYP2A6CYP11B1CYP11B2GABRG2
SCHEMBL12576029 0.82 CYP2A6 (0.55) CYP2A6CYP11B1CYP11B2GABRG2GABRB3
SCHEMBL13778347 0.80 CDK8 (0.48) CDK8CYP2A6LOXL2CYP11B1CYP11B2
SCHEMBL16675071 0.80 CYP2A6 (0.53) CYP2A6CYP11B1CYP11B2GABRG2GABRB3
SCHEMBL27656311 0.80 CYP2A6 (0.41) CYP2A6CYP11B1CYP11B2GABRG2GABRB3
SCHEMBL3723657 0.80 HTR7 (0.44) CYP2A6CYP11B1CYP11B2GABRG2GABRB3
SCHEMBL20797575 0.79 CYP2A6 (0.50) CDK8CYP2A6LOXL2NOS3NOS1
SCHEMBL3670334 0.78 CASP3 (0.48) CYP11B1CYP11B2ENPP2
SCHEMBL3791745 0.78 LOXL2 (0.60) CDK8LOXL2NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314112-B2 Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG (CH) 2012-11-20 US disclosed
CN-101970435-A Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG 2011-02-09 CN disclosed
EP-2242756-A2 PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES Novartis AG (CH) 2010-10-27 EP disclosed
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines NOVARTIS AG (CH) 2009-07-16 US disclosed
WO-2009087225-A2 PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines ALK, ACVR1, PTPN4 CDK8 844/4885CYP2A6 1045/4885LOXL2 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.